Sharp Health Plan
IDHIFA (enasidenib)
Drugs for Cancer : Drugs for Cancer
  • Quantity Limit: limit maximum 3 EA PER fill retail
  • Hepatocellular Carcinoma:
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Duration of Reauthorization: = 12 month(s)
    Diagnosis Types: 2 of Hepatocellular Cancer;Metastatic disease;Unresectable disease
    ECOG Score Requirement Included in Policy: N/A

    Kidney Cancer:
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: Yes
    Duration of Reauthorization: = 12 month(s)
    Drug Policy Based On: NCCN Guidelines
    ECOG Score Requirement Included in Policy: N/A
    Policy Includes Reference to Coverage for Non Clear Cell Histology: No
    If Non-Clear Cell Histology is Referenced in Policy is There a Trial and Failure Requirement: No
    Concomitant Use With: 1 of Afinitor (everolimus);Keytruda

    Thyroid Carcinoma:
    Duration: 12 Month(s)